Sugi Predict

Sugi Predict / Compounds / SCHEMBL15037055

SCHEMBL15037055

SCHEMBL15037055

CCc1ccc(C(=O)N[C@@H](Cc2ccc(-c3ncc(-c4ccc(C(C)(C)C)cc4)cn3)cc2)C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MME P08473 3/20 0.46
▸ ACE P12821 3/20 0.46
▸ ACE2 Q9BYF1 3/20 0.46
▸ PTPN1 P18031 2/20 0.46
▸ PDK1 Q15118 1/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PDK3 Q15120 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ GPR132 Q9UNW8 1/20 0.43
▸ CA2 P00918 5/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CPA1 P15085 2/20 0.43
▸ ITGB1 P05556 1/20 0.43
▸ ITGA4 P13612 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ KIFC1 Q9BW19 2/20 0.42
▸ CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22449211 1.00 L3MBTL1 (0.47) L3MBTL1MMEACEACE2PTPN1
SCHEMBL22449277 0.96 MME (0.49) L3MBTL1MMEACEACE2PTPN1
SCHEMBL15037189 0.96 MME (0.49) L3MBTL1MMEACEACE2PTPN1
SCHEMBL22448948 0.94 MME (0.53) L3MBTL1MMEACEACE2PTPN1
SCHEMBL22449043 0.94 MME (0.53) L3MBTL1MMEACEACE2PTPN1
SCHEMBL15037300 0.94 MME (0.53) L3MBTL1MMEACEACE2PTPN1
SCHEMBL15037188 0.94 MME (0.53) L3MBTL1MMEACEACE2PTPN1
SCHEMBL15037128 0.92 L3MBTL1 (0.48) L3MBTL1MMEACEACE2PTPN1
SCHEMBL15037073 0.92 L3MBTL1 (0.48) L3MBTL1MMEACEACE2PTPN1
SCHEMBL22449248 0.92 PTPN1 (0.46) L3MBTL1MMEACEACE2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-2791112-B1 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES CELGENE INT II SÀRL (CH) 2020-09-23 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885MME 796/4885ACE 3137/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885MME 796/4885ACE 3137/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 728/4885MME 813/4885ACE 3129/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 728/4885MME 813/4885ACE 3129/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885MME 919/4885ACE 2924/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR L3MBTL1 579/4885MME 919/4885ACE 2924/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R L3MBTL1 771/4885MME 796/4885ACE 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback